SMS Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• SMS Pharmaceuticals Ltd reported a 12.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.6%.
• Its expenses for the quarter were up by 16.6% QoQ and down 3.5% YoY.
• The net profit increased 39.4% QoQ and increased 61.0% YoY.
• The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 3.58 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

SMS Pharmaceuticals Ltd is a pharmaceutical company primarily focused on the production and development of active pharmaceutical ingredients (APIs). The company operates in the pharmaceuticals industry, which is known for its competitive nature and stringent regulatory requirements. SMS Pharmaceuticals is committed to maintaining high standards in manufacturing processes and quality control. As of the data available, there are no specific recent major developments or news related to the company provided in the context of this report.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), SMS Pharmaceuticals Ltd reported a total income of ₹240.52 crores. This represents a 12.3% increase quarter-over-quarter (QoQ) from the previous quarter (Q3FY26), where the total income was ₹214.20 crores. However, when compared year-over-year (YoY) with the same quarter in the previous fiscal year (Q4FY25), where the total income was ₹249.62 crores, there is a decrease of 3.6%. This fluctuation in total income is a crucial aspect of understanding the company's revenue performance over the periods.

Profitability

The profitability of SMS Pharmaceuticals Ltd can be gauged by observing the profit before tax and profit after tax figures. In Q4FY26, the company recorded a profit before tax of ₹27.07 crores, which is a 13.1% decrease QoQ and a 5.1% decrease YoY. The tax expense for the quarter was ₹6.10 crores, showing a notable reduction of 23.5% QoQ and 27.7% YoY. Consequently, the profit after tax for the quarter was ₹32.71 crores, marking a significant 39.4% increase QoQ and a 61.0% increase YoY. The earnings per share (EPS) for Q4FY26 was ₹3.58, which increased by 38.2% QoQ and 49.2% YoY.

Operating Metrics

The total expenses for SMS Pharmaceuticals Ltd in Q4FY26 were ₹213.46 crores, reflecting a 16.6% increase QoQ from ₹183.04 crores in Q3FY26. Compared to the previous year (Q4FY25), there was a slight decrease of 3.5% in total expenses. This data suggests variability in the company's operating expenses over the recent quarters and the fiscal year. Understanding these metrics is essential for evaluating the company's operational efficiency and cost management strategies.